LP
TEVA icon

LMR Partners’s Teva Pharmaceuticals TEVA Stock Holding History

LMR Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-152,100
Closed -$4.75M – 1863
2025
Q4 		$4.75M Sell
152,100
-43,000
-22% -$1.06M 0.01% 585
2025
Q3 		$3.94M Sell
195,100
-388,300
-67% -$6.82M 0.02% 573
2025
Q2 		$9.78M Sell
583,400
-8,200
-1% -$132K 0.07% 296
2025
Q1 		$9.09M Buy
+591,600
New +$10.6M 0.09% 264

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

LMR Partners's TEVA Position: Q2 2026 in Review

LMR Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 582,275 shares worth $19.7M. The stake represents 0.07% of the portfolio and ranks #242 among its holdings. This is a return to the name: LMR Partners previously reported a position in TEVA as recently as Q1 2025.

LMR Partners first reported a position in TEVA in Q4 2017 and has held it in 6 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • LMR Partners held 582,275 shares of Teva Pharmaceuticals worth $19.7M as of Q2 2026.
  • Teva Pharmaceuticals was a new LMR Partners position in Q2 2026.
  • Teva Pharmaceuticals made up 0.07% of LMR Partners's portfolio in Q2 2026, its #242 holding.
  • LMR Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.